• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

EuclidSR Partners

edit

Successful venture investing combines two essential components: finding opportunities with significant growth potential and helping to deliver on that potential. It requires a committed approach by experienced investors, not just to building returns but to building companies. Successful investors - armed with deep knowledge of their industries - commit time and focus in addition to capital.

EuclidSR Partners (ESR) provides this kind of commitment - a dedicated approach to life sciences, technology and their convergence, by a highly regarded team of industry experts.

We look to find opportunities with significant growth potential and we work to unlock that potential for our investors. ESR possesses the elements critical for success in today’s venture capital environment

Recent Milestones

edit

• 
  EuclidSR Partners invested in Fluidigm. (11/19/09)
  Posted 11/20/09 at 9:18pm via venturebeat.com
• 
  EuclidSR Partners invested in Rib-X Pharmaceuticals. (1/25/09)
  Posted 4/17/09 at 8:17am via rib-x.com
• 
  EuclidSR Partners invested in Fluidigm. (1/10/07)
  Posted 9/15/09 at 8:33am via venturebeat.com

Investments

Videos

Sources

1. Fluidigm raises another $7.5M for stem-cell analysis chips (venturebeat.com) [edit]
2. Rib-X Pharmaceuticals Announces Positive Phase 2 Study Results for Delafloxacin and a $25 Million Financing (rib-x.com) [edit]
3. Life science fluid control company, Fluidigm, raises $17M more (deals.venturebeat.com) [edit]